ImmunoGen, Amgen forge $35M pact on cancer tech

Waltham, MA-based ImmunoGen struck a deal to license its cancer drug development technology to biotech giant Amgen in a deal that could eventually be worth up to $35 million. Only a million dollars of that, though, is available upfront. Amgen gains the exclusive right to use ImmunoGen's maytansinoid Targeted Antibody Payload technology to develop anticancer therapeutics for an undisclosed target found on solid tumors.

"Amgen has an established track record of success in oncology and an expanding presence in antibody-based therapeutics," says ImmunoGen CEO Daniel Junius. "Amgen's interest in antibody-drug conjugates is good for the field, and we're pleased they've chosen to move forward with ImmunoGen's technology."

Amgen is responsible for the development, manufacturing, and marketing of any products resulting from this license.

- see Immunogen's release for more info 

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.